{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-24-000073","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.269780+00:00","generated_at":"2026-06-01T03:51:30.853361+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurogene doses first patient in high-dose cohort of NGN-401; safety data positive","bullets":["First patient in Cohort 2 received high-dose NGN-401 in May 2024; well-tolerated to date.","Low-dose cohort (3 patients) shows no new treatment-related adverse events; all AEs mild/Grade 1.","No signs of MeCP2 overexpression toxicity, including in patient with mild genetic variant.","Company expects interim efficacy data from low-dose cohort in Q4 2024.","Neurogene is participating in FDA's START Pilot Program to accelerate NGN-401 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-24-000073","json":"https://secwatch.observer/filing/0001404644-24-000073.json","markdown":"https://secwatch.observer/filing/0001404644-24-000073.md","text":"https://secwatch.observer/filing/0001404644-24-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/0001404644-24-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464424000073/ngne-20240618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:51:30.853361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}